205 related articles for article (PubMed ID: 11090553)
1. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates.
Kawauchi M; Suzuki J; Morishita R; Wada Y; Izawa A; Tomita N; Amano J; Kaneda Y; Ogihara T; Takamoto S; Isobe M
Circ Res; 2000 Nov; 87(11):1063-8. PubMed ID: 11090553
[TBL] [Abstract][Full Text] [Related]
2. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.
Morishita R; Gibbons GH; Horiuchi M; Ellison KE; Nakama M; Zhang L; Kaneda Y; Ogihara T; Dzau VJ
Proc Natl Acad Sci U S A; 1995 Jun; 92(13):5855-9. PubMed ID: 7597041
[TBL] [Abstract][Full Text] [Related]
3. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.
Tomita N; Horiuchi M; Tomita S; Gibbons GH; Kim JY; Baran D; Dzau VJ
Am J Physiol; 1998 Aug; 275(2):F278-84. PubMed ID: 9691019
[TBL] [Abstract][Full Text] [Related]
4. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.
Ehsan A; Mann MJ; Dell'Acqua G; Dzau VJ
J Thorac Cardiovasc Surg; 2001 Apr; 121(4):714-22. PubMed ID: 11279413
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for heart transplantation-associated coronary arteriosclerosis.
Isobe M; Suzuki J; Morishita R; Kaneda Y; Amano J
Ann N Y Acad Sci; 2000 May; 902():77-83. PubMed ID: 10865827
[TBL] [Abstract][Full Text] [Related]
6. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts.
Suzuki J; Morishita R; Amano J; Kaneda Y; Isobe M
Gene Ther; 2000 Nov; 7(21):1847-52. PubMed ID: 11110417
[TBL] [Abstract][Full Text] [Related]
7. Antisense Bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts.
Suzuki J; Isobe M; Morishita R; Nishikawa T; Amano J; Kaneda Y
Cardiovasc Res; 2000 Feb; 45(3):783-7. PubMed ID: 10728401
[TBL] [Abstract][Full Text] [Related]
8. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
Mann MJ; Whittemore AD; Donaldson MC; Belkin M; Conte MS; Polak JF; Orav EJ; Ehsan A; Dell'Acqua G; Dzau VJ
Lancet; 1999 Oct; 354(9189):1493-8. PubMed ID: 10551494
[TBL] [Abstract][Full Text] [Related]
9. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide.
Suzuki J; Isobe M; Morishita R; Aoki M; Horie S; Okubo Y; Kaneda Y; Sawa Y; Matsuda H; Ogihara T; Sekiguchi M
Nat Med; 1997 Aug; 3(8):900-3. PubMed ID: 9256282
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis.
Tomita N; Kim JY; Gibbons GH; Zhang L; Kaneda Y; Stahl RA; Ogborn M; Venderville B; Morishita R; Baran D; Dzau VJ
Int J Mol Med; 2004 May; 13(5):629-36. PubMed ID: 15067361
[TBL] [Abstract][Full Text] [Related]
11. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model.
Nakamura T; Morishita R; Asai T; Tsuboniwa N; Aoki M; Sakonjo H; Yamasaki K; Hashiya N; Kaneda Y; Ogihara T
Gene Ther; 2002 Apr; 9(8):488-94. PubMed ID: 11948373
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of cultured human Tenon's fibroblastic cells by targeting the E2F transcription factor.
Akimoto M; Hangai M; Okazaki K; Kogishi J; Honda Y; Kaneda Y
Exp Eye Res; 1998 Oct; 67(4):395-401. PubMed ID: 9820786
[TBL] [Abstract][Full Text] [Related]
13. Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries.
Kume M; Komori K; Matsumoto T; Onohara T; Takeuchi K; Yonemitsu Y; Sugimachi K
Circulation; 2002 Mar; 105(10):1226-32. PubMed ID: 11889018
[TBL] [Abstract][Full Text] [Related]
14. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia.
Ahn JD; Morishita R; Kaneda Y; Kim HS; Chang YC; Lee KU; Park JY; Lee HW; Kim YH; Lee IK
Gene Ther; 2002 Dec; 9(24):1682-92. PubMed ID: 12457282
[TBL] [Abstract][Full Text] [Related]
15. E2F decoy oligodeoxynucleotides on neointimal hyperplasia in canine vein graft.
Cho WH; Lee SO; Kim HT; Ahn JD; Lee IK
Transplant Proc; 2005; 37(1):77-9. PubMed ID: 15808553
[TBL] [Abstract][Full Text] [Related]
16. Suppression of proliferative cholangitis by E2F decoy oligodeoxynucleotide.
Yoshida M; Yamamoto N; Nitta T; Uehara T; Terao R; Hatano E; Iimuro Y; Yamaoka Y
J Surg Res; 2002 Feb; 102(2):95-101. PubMed ID: 11796004
[TBL] [Abstract][Full Text] [Related]
17. E2F decoy oligonucleotide for genetic engineering of vascular bypass grafts.
Mann MJ
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):171-6. PubMed ID: 9593059
[No Abstract] [Full Text] [Related]
18. Prevention of cardiac allograft arteriosclerosis using antisense proliferating-cell nuclear antigen oligonucleotide.
Suzuki J; Isobe M; Morishita R; Nishikawa T; Amano J; Kaneda Y
Transplantation; 2000 Jul; 70(2):398-400. PubMed ID: 10933173
[TBL] [Abstract][Full Text] [Related]
19. In vivo reduction of the nuclear factor-kappaB activity using synthetic cis-element decoy oligonucleotides suppresses intimal hyperplasia in the injured carotid arteries in rabbits.
Takeuchi K; Itoh H; Yonemitsu Y; Matsumoto T; Kume M; Komori K; Maehara Y
Surg Today; 2007; 37(7):575-83. PubMed ID: 17593477
[TBL] [Abstract][Full Text] [Related]
20. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.
Morishita R; Gibbons GH; Ellison KE; Nakajima M; von der Leyen H; Zhang L; Kaneda Y; Ogihara T; Dzau VJ
J Clin Invest; 1994 Apr; 93(4):1458-64. PubMed ID: 8163650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
